Invention Grant
- Patent Title: VSV/NDV hybrid viruses for oncolytic therapy of cancer
-
Application No.: US16097748Application Date: 2017-05-18
-
Publication No.: US10906942B2Publication Date: 2021-02-02
- Inventor: Oliver Ebert , Jennifer Altomonte
- Applicant: KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN
- Applicant Address: DE Munich
- Assignee: KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN
- Current Assignee: KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITÄT MÜNCHEN
- Current Assignee Address: DE Munich
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Priority: EP16170445 20160519
- International Application: PCT/EP2017/062007 WO 20170518
- International Announcement: WO2017/198779 WO 20171123
- Main IPC: C07K14/005
- IPC: C07K14/005 ; A61K9/00 ; A61K35/766 ; A61K38/16 ; A61K38/47 ; A61K45/06 ; C12N9/24 ; C12N15/86 ; A61K38/00 ; A61K49/00

Abstract:
The present invention relates to recombinant oncolytic viruses comprising a vesicular stomatitis virus (VSV), wherein the glycoprotein (G protein) of VSV is deleted; and which comprises a modified fusion protein (F protein) of Newcastle disease virus (NDV); and the hemagglutinin neuraminidase (HN) protein of NDV. The present invention further relates to nucleic acids encoding for the recombinant oncolytic virus and vectors comprising the nucleic acids. The present invention further relates to pharmaceutical compositions comprising the rVSV of the invention, the nucleic acid or the vector, further to uses as gene delivery tool and/or for tumor detection. The present invention further relates to the recombinant oncolytic vesicular stomatitis virus (VSV) for use in medicine, in particular for the diagnosis, prevention and/or treatment of cancer.
Public/Granted literature
- US20190153039A1 VSV/NDV HYBRID VIRUSES FOR ONCOLYTIC THERAPY OF CANCER Public/Granted day:2019-05-23
Information query